Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Capital Expenditures (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Capital Expenditures for 15 consecutive years, with $1.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Expenditures fell 95.72% year-over-year to $1.6 million, compared with a TTM value of $2.2 million through Dec 2025, down 94.24%, and an annual FY2025 reading of $2.2 million, down 94.24% over the prior year.
  • Capital Expenditures was $1.6 million for Q4 2025 at Neurocrine Biosciences, up from -$1.3 million in the prior quarter.
  • Across five years, Capital Expenditures topped out at $37.4 million in Q4 2024 and bottomed at -$7.9 million in Q2 2024.
  • Average Capital Expenditures over 4 years is $3.3 million, with a median of $200000.0 recorded in 2023.
  • Peak annual rise in Capital Expenditures hit 2237.5% in 2024, while the deepest fall reached 4050.0% in 2024.
  • Year by year, Capital Expenditures stood at $100000.0 in 2021, then soared by 1500.0% to $1.6 million in 2023, then soared by 2237.5% to $37.4 million in 2024, then crashed by 95.72% to $1.6 million in 2025.
  • Business Quant data shows Capital Expenditures for NBIX at $1.6 million in Q4 2025, -$1.3 million in Q3 2025, and -$800000.0 in Q2 2025.